Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus

Published:2022-05 Issue: Volume:170 Page:128-131
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Hammerman Ariel^ORCID,Moore Candace Makeda^ORCID,Aboalhasan Enis^ORCID,Azuri Joseph,Arbel Ronen^ORCID

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I;Paneni;Eur Heart J,2013

2. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis;McGuire;JAMA Cardiol,2021

3. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials;Jia;Cardiovasc Drugs Ther,2018

4. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

5. Pioneer 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Husain;N Engl J Med,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10

2. Therapie des Typ-2-Diabetes;Die Diabetologie;2024-01-30

3. Treatment of type 2 diabetes;Die Diabetologie;2023-04-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP